Kairos Pharma, Ltd. KAPA
0.51 USD +0.03 (+6.65%)
At closeNov 3, 2026, 7:55 PM EST
0.53 +0.02 +4.75%
After hours · Nov 3, 7:55 PM ET
0.4182 Day range 0.505
0.4182 52-week range 7.28
- YTD
- -89.84%
- 1 year
- -92.86%
News
businesswire.com Kairos Pharma Presents at United Scientific Group's 11th International Conference on Cancer Research & Drug Development LOS ANGELES--(BUSINESS WIRE)--Neil Bhowmick, President and CSO of Kairos Pharma, presents on lead candidate ENV-105 and its interim efficacy results at Cancer R&D 2026.
newsfilecorp.com CEO.CA's Inside the Boardroom: Major U.S. Cancer Centers Are Testing This New Drug: Kairos Pharma Toronto, Ontario--(Newsfile Corp. - October 22, 2026) - CEO.CA ("CEO.CA"), the leading investor social network in venture stocks, shares exclusive updates with CEOs and executives from around the…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Profound Medical (NASDAQ:PROF) shares moved upwards by 21.5% to $6.9 during Thursday's pre-market session. The company's market cap stands at $207.5 million. Haemonetics (NYSE:HAE) stock…- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Valneva (NASDAQ:VALN) shares rose 20.6% to $7.09 during Wednesday's after-market session. The company's market cap stands at $555.6 million. Profound Medical (NASDAQ:PROF) stock rose 16.98%…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) shares increased by 186.0% to $3.58 during Wednesday's regular session. Sunshine Biopharma (NASDAQ:SBFM) stock moved upwards by 151.31% to $1.0. The…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) stock increased by 59.2% to $1.99 during Wednesday's pre-market session. Lipocine (NASDAQ:LPCN) shares rose 52.38% to $3.2. The company's market cap…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) shares moved upwards by 64.0% to $2.05 during Tuesday's after-market session. The market value of their outstanding shares is at $1.1 million. Neogen…
benzinga.com Kairos Pharma Targets Drug Resistance Mechanism Against Prostate Cancer Kairos Pharma Ltd. (NYSE:KAPA) on Tuesday announced interim efficacy results from its ongoing Phase 2 clinical trial testing ENV-105 alongside apalutamide for patients with metastatic…
benzinga.com Kairos Pharma Targets Drug Resistance Mechanism Against Prostate Cancer Kairos Pharma evaluates ENV-105 with apalutamide in a Phase 2 trial targeting drug-resistant metastatic prostate cancer patients.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Apimeds Pharmaceuticals (AMEX:APUS) shares moved upwards by 52.5% to $7.0 during Tuesday's regular session. The company's market cap stands at $6.9 million. Option Care Health (NASDAQ:OPCH)…
businesswire.com Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer LOS ANGELES--(BUSINESS WIRE)---- $KAPA--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company addressing drug resistance in cancer, today announced positive interim…
businesswire.com Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA LOS ANGELES--(BUSINESS WIRE)---- $KAPA--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that Neil…
businesswire.com Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference LOS ANGELES--(BUSINESS WIRE)---- $KAPA #HCW--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that John…- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Aethlon Medical (NASDAQ:AEMD) stock rose 50.7% to $3.27 during Thursday's after-market session. The market value of their outstanding shares is at $1.6 million. Modular Medical (NASDAQ:MODD)…
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Innovative Eyewear (NASDAQ:LUCY) stock rose 63.6% to $1.12 during Monday's regular session. The market value of their outstanding shares is at $5.8 million. Picard Medical (AMEX:PMI) shares…
benzinga.com Stock Market Today: Dow Jones, S&P 500, Nasdaq 100 Futures Slip Ahead of Data-Heavy Week, Nvidia Earnings, and Jackson Hole—BABA, PMI, BIRK in Focus (UPDATED) U.S. stock futures were mixed on Monday, as the Dow Jones index rose, the S&P 500 and Nasdaq 100 indices fell, after Friday's higher close.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Picard Medical (AMEX:PMI) shares moved upwards by 34.6% to $4.32 during Monday's pre-market session. The company's market cap stands at $6.5 million. As per the press release, Q2 earnings…
benzinga.com Applied Optoelectronics, PDD Holdings And 3 Stocks To Watch Heading Into Monday U.S. stock futures up, PDD, AAOI, and XPEV to report earnings, KAPA announces reverse stock split, GRRR expected to post earnings after close.
benzinga.com Kairos Pharma Announces 1-For-7 Reverse Stock Split, Effective Sept. 1 Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced that it will conduct a reverse stock split of its outstanding…
businesswire.com Kairos Pharma Announces 1-for-7 Reverse Stock Split LOS ANGELES--(BUSINESS WIRE)---- $KAPA--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced that it…- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Zhengye Biotechnology (NASDAQ:ZYBT) shares moved upwards by 24.0% to $1.71 during Wednesday's after-market session. The market value of their outstanding shares is at $135.0 million. Medpace…
- benzinga.com Kairos Pharma Partners With Bayer To Mull ENV-105 Inhibitor In Combination With Bayer’s XOFIGO Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced a strategic collaboration with Bayer to evaluate…
businesswire.com Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer LOS ANGELES--(BUSINESS WIRE)---- $KAPA #Bayer--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced a…- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Anixa Biosciences (NASDAQ:ANIX) shares rose 10.0% to $3.65 during Friday's pre-market session. The market value of their outstanding shares is at $112.9 million. Barinthus Biotherapeutics…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers AtaiBeckley (NASDAQ:ATAI) stock rose 34.3% to $7.2 during Thursday's pre-market session. The market value of their outstanding shares is at $1.9 billion. Agape ATP (NASDAQ:ATPC) shares moved…
benzinga.com Why JB Hunt Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket JB Hunt Transport Services Inc (JBHT) beat earnings and revenue estimates, causing shares to surge 7.9% in pre-market trading. Other top gainers include ATPC, TGHL, ATAI, DXST, KAPA, EHGO, HELP, VSA,…
benzinga.com Kairos Pharma (KAPA) Stock Surges Over 22% After Hours: Why is it Moving? Kairos Pharma shares surged 22.64% after hours following positive interim safety data from its lead cancer drug candidate ENV-105.
newsfilecorp.com CEO.CA's Inside the Boardroom: Kairos Pharma Might Change Cancer Treatment Forever Toronto, Ontario--(Newsfile Corp. - July 15, 2026) - CEO.CA ("CEO.CA"), the leading investor social network in junior resource and venture stocks, shares exclusive updates with CEOs of junior mining…
businesswire.com Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Market LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company addressing drug resistance in cancer, today announced compelling interim safety…
zacks.com All You Need to Know About Kairos Pharma, Ltd. (KAPA) Rating Upgrade to Buy Kairos Pharma, Ltd. (KAPA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
newsfilecorp.com Kapa Gold Announces the Results of Its 2026 Annual General Meeting Vancouver, British Columbia--(Newsfile Corp. - June 19, 2026) - KAPA GOLD INC. (TSXV: KAPA) ("Kapa" or the "Company") is pleased to announce the results of its annual meeting of shareholders held…
businesswire.com Kairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to Shareholders LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, provides a mid-year update for 2026 and a…
businesswire.com Kairos Pharma Receives GHP Magazine's Healthcare & Pharmaceutical Award LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, announces that it has been named a winner…
newsfilecorp.com Kairos Pharma, Ltd. to Present at the LD Micro Invitational XVI Los Angeles, California--(Newsfile Corp. - May 13, 2026) - Kairos Pharma, Ltd. (NYSE American: KAPA) announced today that it will be participating in the 16th Annual LD Micro Invitational at the Luxe…
businesswire.com Kairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual Filings LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, announces that its Annual Meeting of…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
globenewswire.com KAPA Investors Have Opportunity to Join Kairos Pharma, Ltd. Fraud Investigation with the Schall Law Firm LOS ANGELES, April 28, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kairos Pharma,…
businesswire.com Kairos Pharma Recognized with Pinnacle Award for Excellence in Healthcare Innovation LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, announces that it has been named a winner…
businesswire.com Kairos Pharma Investor News: Rosen Law Firm Encourages Kairos Pharma, Ltd. Investors to Inquire About Securities Class Action Investigation – KAPA NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Kairos Pharma, Ltd. (NYSE…
businesswire.com Rosen Law Firm Encourages Kairos Pharma, Ltd. Investors to Inquire About Securities Class Action Investigation – KAPA NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Kairos Pharma, Ltd. (NYSE…
benzinga.com Kairos Pharma Q4 EPS $(0.07) Beats $(0.10) Estimate Kairos Pharma (AMEX:KAPA) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.10) by 30 percent. This is a 12.5 percent increase over losses of $(0.08) per…
benzinga.com Kairos Pharma Enters Into Binding Terms To Acquire CL-273 From Celyn Therapeutics For Undisclosed Sum; Transaction Is Expected To Be Value‑Accretive The next‑generation, AI‑designed pan‑EGFR inhibitor for EGFR‑mutant lung cancer significantly expands the Company's oncology pipeline Targeting a $16.2 Billion Market OpportunityKairos Pharma, Ltd.…
businesswire.com Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces that it has entered into…- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com Kairos Pharma Signs Deal To Acquire Two Experimental Lung Cancer Drug Candidates From Celyn Therapeutics, Financial Terms Undisclosed Kairos Pharma, Ltd. (NYSE: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces the signing of a term sheet for a strategic asset acquisition…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session